Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the 1st-line procedure of CML-CP. 5 hundred and nineteen people with recently diagnosed CML-CP ended up randomly assigned to acquire dasatinib in a dose of a hundred mg once day by day (259 people) https://anacardicacid21098.total-blog.com/new-step-by-step-map-for-itd-1-53959525